Pyrvinium pamoate
Based on 21 publication(s) in Google Scholar
Pyrvinium pamoate is an FDA-approved antihelmintic agent that inhibits WNT pathway signaling.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 3546-41-6
- Formula: C26H28N3.1/2 C23H14O6
- Molecular Weight:575.70
-
Storage:
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pyrvinium pamoate
More- Mol Cancer. 2025 Dec 18;24(1):310. [Abstract]
- Neuro Oncol. 2026 Jan 7:noaf297. [Abstract]
- Cell Death Discov. 2021 Oct 12;7(1):288. [Abstract]
- Cell Mol Neurobiol. 2026 Jan 24;46(1):36.
- Cell Oncol (Dordr). 2026 Jan 14;49(1):25. [Abstract]
- Bioorg Chem. 2026 Jul 5:175:109753. [Abstract]
- Transl Oncol. 2021 May;14(5):101048. [Abstract]
- J Proteome Res. 2025 Jul 4;24(7):3578-3596. [Abstract]
- BMC Cancer. 2024 Nov 16;24(1):1415. [Abstract]
- Endocrinology. 2023 Mar 13;164(5):bqad042. [Abstract]
- Am J Cancer Res. 2022 Nov 15;12(11):5226-5240. [Abstract]
- J Biochem Mol Toxicol. 2024 Nov;38(11):e70010. [Abstract]
- Anal Biochem. 2019 Dec 15;587:113463. [Abstract]
- Methods Appl Fluoresc. 2021 Jun 4;9(3). [Abstract]
- bioRxiv. 2025 Sep 17.
- University of Pittsburgh. 2025.
- bioRxiv. 2024 September 07.
- bioRxiv. 2024 September 07.
- bioRxiv. 2025 Apr 28:2024.04.18.590103. [Abstract]
- bioRxiv. May 20, 2022.
- bioRxiv. 2020 Mar.
Customer Validation & Images
-
WB
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
WB
-
Flow Cytometry
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BHK-21 | CC50 |
>20 μM
Compound: 66
|
cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay
cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay
|
[PMID: 32845145] |
| LLC-MK2 | CC50 |
>20 μM
Compound: 66
|
Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay
Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay
|
[PMID: 32845145] |
Pyrvinium pamoate (0-500 nM) inhibits proliferation of MCF-7 (luminal), MDA-MB-231 (claudin-low), MDA-MB-468 (basal-like) and SkBr3 (HER2-OE) cells in a dose-dependent manner, with IC50 value of 1170±105.0 nM against MDA-MB-231 cell line. Pyrvinium pamoate significantly inhibits self-renewal and proliferation of BCSCs, and suppresses BCSC population with a distinct phenotype. Pyrvinium pamoate significantly decreases average expression levels of FZD1, FZD10, WNT1, WNT7B, CTNNB1, MYC, and LRP5 at transcriptional level. Moreover, Pyrvinium pamoate also efficiently down-regulates the expression of other stemness genes including ALDH1, CD44 and ABCG2[1]. Pyrvinium pamoate blocks colon cancer cell growth in vitro in a dose-dependent manner with great differences in the inhibitory concentration (IC50), ranging from 0.6 to 65 μM for colon cancer cells with mutations in WNT signaling. Pyrvinium pamoate decreases messenger RNA (mRNA) and protein levels of known WNT target genes as c-MYC and thereby led to the induction of p21[2]. Pyrvinium pamoate ultimately inhibits Wnt signalling despite its lack of efficacy on CK1[3]. Pyrvinium pamoate imposes specific toxicity on cardiac fibroblasts in ischemia (IC50=9.5 nM). The cytotoxic effect of Pyrvinium pamoate on cardiac fibroblasts specifically under glucose- and glutamine-deficient condition[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 3546-41-6
-
Appearance Solid
-
Molecular Weight 575.70
-
Formula C26H28N3.1/2 C23H14O6
-
Color Red to reddish brown
-
SMILES
C[N+]1=C2C=CC(N(C)C)=CC2=CC=C1/C=C/C3=C(C)N(C4=CC=CC=C4)C(C)=C3.C[N+]5=C6C=CC(N(C)C)=CC6=CC=C5/C=C/C7=C(C)N(C8=CC=CC=C8)C(C)=C7.O=C(C9=C(O)C(CC%10=C%11C=CC=CC%11=CC(C([O-])=O)=C%10O)=C%12C=CC=CC%12=C9)[O-]
-
Synonyms
Pyrvinium embonate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
2025 Dec 18;24(1):310. PMID: 41413567
Pyrvinium pamoate purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Dec 18;24(1):310. [Abstract]
To corroborate Wnt pathway involvement in melanoma cell-ITGB2:ICAM-1 functions, we employed three independent pharmacologic Wnt signaling antagonists, including FDA-approved Pyrvinium pamoate (6.5 μM, 20 min-12 h), repurposed for cancer therapy, as well as LGK974 and Zamaporvint. All three Wnt inhibitors not only suppressed canonical and, to a lesser extent, non-canonical Wnt signaling.
Pyrvinium pamoate purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Dec 18;24(1):310. [Abstract]
Relative in vitro adhesion (mean ± SEM) to immobilized ICAM-1 as determined by CellTiter-Glo-based luminescence analysis of Itgb2 KO versus Cas9 control YUMM5.2 variants and anti-murine ITGB2 blocking ab versus isotype control ab treated YUMM5.2 wildtype cells, in the combined presence or absence of Pyrvinium pamoate (6.5 μM, 20 min-12 h), LGK974, Zamaporvint, or vehicle control.
Pyrvinium pamoate purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Dec 18;24(1):310. [Abstract]
Itgb2 KO or administration of Pyrvinium pamoate (0.3 mg/kg, ip, daily), LGK974, or Zamaporvint significantly suppressed YUMM5.2 tumor growth in NSG and C57BL/6 hosts compared to controls.
-
Neuro Oncol
MBD3 deficiency decommissions the NuRD complex and orchestrates the epigenetic regulation of gene expression to suppress neuroblastoma progression. [Abstract]2026 Jan 7:noaf297. PMID: 41499431 -
Cell Death Discov
Pyrvinium pamoate regulates MGMT expression through suppressing the Wnt/β-catenin signaling pathway to enhance the glioblastoma sensitivity to temozolomide. [Abstract]2021 Oct 12;7(1):288. PMID: 34642308
Pyrvinium pamoate purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2021 Oct 12;7(1):288. [Abstract]
LN18 and T98G cells were subjected to Pyrvinium pamoate (0-4 μM) treatment at various concentrations for 48 h, and then flow cytometry was carried out along with annexin V-FITC and PI staining (left panel). The elevated apoptotic cells were quantified and presented in the histogram (right panel).
Pyrvinium pamoate purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2021 Oct 12;7(1):288. [Abstract]
The protein levels of PARP-1, Bcl-2, Bax, caspase-9, cleaved caspase-3, and survivin were evaluated through western blotting following Pyrvinium pamoate (0-4 μM) treatment at different contents.
Pyrvinium pamoate purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2021 Oct 12;7(1):288. [Abstract]
PI staining combined with flow cytometry showed cell cycle distribution in the LN18 and T98G cell lines following Pyrvinium pamoate (0-4 μM, 48 h) treatment at different contents.
Pyrvinium pamoate purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2021 Oct 12;7(1):288. [Abstract]
Surface plots of LN18 and T98G cells treated with TMZ, Pyrvinium pamoate, or combined TMZ + Pyrvinium pamoate shown in 2D and 3D. Plots were generated using Combenefit program by applying HSA model.
-
-
Cell Oncol (Dordr)
Upregulated ARMCX1 suppresses nasopharyngeal carcinoma progression by promoting TRIM21-mediated β-catenin degradation. [Abstract]2026 Jan 14;49(1):25. PMID: 41533266 -
Bioorg Chem
Pyrvinium pamoate inhibits the survival of intracellular Mycobacterium tuberculosis through suppression of macrophage ferroptosis. [Abstract]2026 Jul 5:175:109753. PMID: 41875752 -
Transl Oncol
High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia. [Abstract]2021 May;14(5):101048. PMID: 33667892 -
J Proteome Res
Quantitative Proteomics Unveils the Synergistic Effects of Combination Drugs on Cytoskeleton Composition and Autophagy-Mediated Cell Death in Neuroblastoma. [Abstract]2025 Jul 4;24(7):3578-3596. PMID: 40526398 -
BMC Cancer
Exploring the impact of mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 on breast cancer cell metabolism. [Abstract]2024 Nov 16;24(1):1415. PMID: 39550554 -
Endocrinology
2023 Mar 13;164(5):bqad042. PMID: 36929849 -
Am J Cancer Res
KIF3A inhibits nasopharyngeal carcinoma proliferation, migration and invasion by interacting with β-catenin to suppress its nuclear accumulation. [Abstract]2022 Nov 15;12(11):5226-5240. PMID: 36504907
Pyrvinium pamoate purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2022 Nov 15;12(11):5226-5240. [Abstract]
Pyrvinium pamoate, a specific inhibitor of the Wnt pathway, is used to treat KIF3A knockdown cells. Pyrvinium pamoate blocks Wnt pathway can reverse the effects induced by KIF3A siRNA in HONE1 and SUNE1 cells.
-
J Biochem Mol Toxicol
WNT1/ROR2 pathway enhances the Triple-Negative breast cancer invasion, migration, and Epithelial-Mesenchymal transition. [Abstract]2024 Nov;38(11):e70010. PMID: 39428718 -
Anal Biochem
Inhibitor screening assay for neurexin-LRRTM adhesion protein interaction involved in synaptic maintenance and neurological disorders. [Abstract]2019 Dec 15;587:113463. PMID: 31574254 -
Methods Appl Fluoresc
Using FDA-approved drugs as off-label fluorescent dyes for optical biopsies: from in silico design to ex vivo proof-of-concept. [Abstract]2021 Jun 4;9(3). PMID: 34044380 -
-
-
-
-
bioRxiv
2025 Apr 28:2024.04.18.590103. PMID: 38659924 -
-
Solvent & Solubility
DMSO : 16.67 mg/mL (28.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (2.90 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.67 mg/mL (2.90 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Pyrvinium pamoate is dissolved in DMSO at a concentration of 1 μM and is stocked in aliquots at -20°C. Cells (1×104) are suspended in 200 μL culture medium and then seeded into 96-well plates in quintuplicate overnight. Cells are treated with indicated concentrations of Pyrvinium pamoate (0-8,000 μM). After incubating for 3 days, CCK8 (10 μL) is added into each well and incubated at 37°C for 1 h. The absorbance is measured using a microplate reader at 450 nm[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: NOD/SCID mice are housed under aseptic conditions in individually ventilated cages. For xenografting, 5×106 Pyrvinium pamoate-pretreated or untreated breast cancer cells (MDA-MB-231) are resuspended in a 1:1 mixture of culture medium and Matrigel and then transplanted into the fourth pair of mammary fat pads of mice (4-6-week-old). After injection, tumor size is measured by calipers each day and tumor growth is plotted. Upon reaching the endpoint, mice are sacrificed and tumors are harvested. All the tumors are formalin-fixed, and paraffin-embedded for hematoxylin and eosin and immunohistochemical staining[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Xu L, et al. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells. Int J Oncol. 2016 Mar;48(3):1175-86. [Content Brief]
[2]. Wiegering A, et al. The impact of pyrvinium pamoate on colon cancer cell viability. Int J Colorectal Dis. 2014 Oct;29(10):1189-98. [Content Brief]
[3]. Venerando A, et al. Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. Biochem J. 2013 May 15;452(1):131-7. [Content Brief]
[4]. Murakoshi M, et al. An anthelmintic drug, pyrvinium pamoate, thwarts fibrosis and ameliorates myocardial contractile dysfunction in a mouse model of myocardial infarction. PLoS One. 2013 Nov 4;8(11):e79374. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7370 mL | 8.6851 mL | 17.3702 mL | 43.4254 mL |
| 5 mM | 0.3474 mL | 1.7370 mL | 3.4740 mL | 8.6851 mL | |
| 10 mM | 0.1737 mL | 0.8685 mL | 1.7370 mL | 4.3425 mL | |
| 15 mM | 0.1158 mL | 0.5790 mL | 1.1580 mL | 2.8950 mL | |
| 20 mM | 0.0869 mL | 0.4343 mL | 0.8685 mL | 2.1713 mL | |
| 25 mM | 0.0695 mL | 0.3474 mL | 0.6948 mL | 1.7370 mL |
Pyrvinium pamoate Related Classifications
HY-A0293 Related Classifications
Powered by Bioz